1319211-95-4 Usage
Uses
Used in Pharmaceutical Development:
(1S,2S)-ethyl 2-(4-(5-iodo-1H-imidazol-4-yl)phenyl)cyclopropanecarboxylate is utilized as a key intermediate in the synthesis of pharmaceuticals, capitalizing on the imidazole group's potential to exhibit biological activity. The unique structural features of (1S,2S)-ethyl 2-(4-(5-iodo-1H-imidazol-4-yl)phenyl)cyclopropanecarboxylate may contribute to the development of new drugs with specific therapeutic targets.
Used in Medicinal Chemistry Research:
In the realm of medicinal chemistry, (1S,2S)-ethyl 2-(4-(5-iodo-1H-imidazol-4-yl)phenyl)cyclopropanecarboxylate serves as a valuable compound for studying the structure-activity relationships of molecules containing imidazole moieties. Its properties can be explored for potential binding affinities to various biological targets, aiding in the design of more effective drugs.
Used in Neurological Disorder Research:
(1S,2S)-ethyl 2-(4-(5-iodo-1H-imidazol-4-yl)phenyl)cyclopropanecarboxylate is used as a research tool in investigating neurological disorders. The presence of the imidazole group may allow it to interact with components of the central nervous system, providing insights into the development of treatments for such conditions.
Used in Antimicrobial Studies:
Due to the inclusion of the iodine group, (1S,2S)-ethyl 2-(4-(5-iodo-1H-imidazol-4-yl)phenyl)cyclopropanecarboxylate is employed in research aimed at understanding and developing new antimicrobial agents. The iodine atom may confer antimicrobial properties, making (1S,2S)-ethyl 2-(4-(5-iodo-1H-imidazol-4-yl)phenyl)cyclopropanecarboxylate a candidate for studies on infectious diseases and potential therapeutic interventions.
Used in Chemical Synthesis:
In the chemical synthesis industry, (1S,2S)-ethyl 2-(4-(5-iodo-1H-imidazol-4-yl)phenyl)cyclopropanecarboxylate is used as a building block for creating more complex organic molecules. Its unique structure can be leveraged to form a variety of compounds with diverse applications in different fields.
Check Digit Verification of cas no
The CAS Registry Mumber 1319211-95-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,1,9,2,1 and 1 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1319211-95:
(9*1)+(8*3)+(7*1)+(6*9)+(5*2)+(4*1)+(3*1)+(2*9)+(1*5)=134
134 % 10 = 4
So 1319211-95-4 is a valid CAS Registry Number.
1319211-95-4Relevant academic research and scientific papers
Discovery of MK-3168: A PET tracer for imaging brain fatty acid amide hydrolase
Liu, Ping,Hamill, Terence G.,Chioda, Marc,Chobanian, Harry,Fung, Selena,Guo, Yan,Chang, Linda,Bakshi, Raman,Hong, Qingmei,Dellureficio, James,Lin, Linus S.,Abbadie, Catherine,Alexander, Jessica,Jin, Hong,Mandala, Suzanne,Shiao, Lin-Lin,Li, Wenping,Sanabria, Sandra,Williams, David,Zeng, Zhizhen,Hajdu, Richard,Jochnowitz, Nina,Rosenbach, Mark,Karanam, Bindhu,Madeira, Maria,Salituro, Gino,Powell, Joyce,Xu, Ling,Terebetski, Jenna L.,Leone, Joseph F.,Miller, Patricia,Cook, Jacquelynn,Holahan, Marie,Joshi, Aniket,O'Malley, Stacey,Purcell, Mona,Posavecz, Diane,Chen, Tsing-Bau,Riffel, Kerry,Williams, Mangay,Hargreaves, Richard,Sullivan, Kathleen A.,Nargund, Ravi P.,DeVita, Robert J.
, p. 509 - 513 (2013/07/26)
We report herein the discovery of a fatty acid amide hydrolase (FAAH) positron emission tomography (PET) tracer. Starting from a pyrazole lead, medicinal chemistry efforts directed toward reducing lipophilicity led to the synthesis of a series of imidazole analogues. Compound 6 was chosen for further profiling due to its appropriate physical chemical properties and excellent FAAH inhibition potency across species. [11C]-6 (MK-3168) exhibited good brain uptake and FAAH-specific signal in rhesus monkeys and is a suitable PET tracer for imaging FAAH in the brain.
IMIDAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH AND AS FAAH IMAGING AGENTS
-
Page/Page column 47, (2010/09/18)
The present invention is directed to certain Inidazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds
